Cargando…

Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study

BACKGROUND: It is crucial to determine whether infliximab (IFX) therapy could be safely interrupted in Crohn’s disease (CD) patients with clinical remission. The outcome and risk predictors of relapse after IFX therapy stopped are controversial. The aim was to assess the relapse and predictive facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Huiqin, Xiang, Cheng, Qiu, Chen, Chen, Zhao, Huang, Silin, Liang, Li, Wang, Xinying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412541/ https://www.ncbi.nlm.nih.gov/pubmed/28496529 http://dx.doi.org/10.14740/gr800w

Ejemplares similares

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Outcomes of Pediatric Patients with Crohn's Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
por: Lv, Yao, et al.
Publicado: (2022)

Early Start of Infliximab in Crohn’s Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort
por: Schnitzler, Fabian, et al.
Publicado: (2021)

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
por: Buhl, Sine Schnoor, et al.
Publicado: (2014)

Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center
por: Takai, Chinatsu, et al.
Publicado: (2020)

Erratum for Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center
por: Takai, Chinatsu, et al.
Publicado: (2021)

The Reasons for Discontinuation of Infliximab Treatment in Patients with Crohn's Disease: A Review of Practice at NHS Teaching Hospital
por: Krupa, Lukasz Z., et al.
Publicado: (2011)

Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study
por: Komaki, Yuga, et al.
Publicado: (2021)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
por: Jung, Dai, et al.
Publicado: (2017)

The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China
por: Zhang, Tianyu, et al.
Publicado: (2016)

Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy
por: Dai, Cong, et al.
Publicado: (2014)

Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
por: Verma, Sanam, et al.
Publicado: (2013)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
por: Li, Shuyan, et al.
Publicado: (2023)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Infliximab Combined with Enteral Nutrition for Managing Crohn's Disease Complicated with Intestinal Fistulas
por: Wu, Xiao-Li, et al.
Publicado: (2016)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review
por: Hu, Huiqin, et al.
Publicado: (2016)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Infliximab response associates with radiologic findings in bio-naïve Crohn’s disease
por: Yueying, Chen, et al.
Publicado: (2023)

Remission of Refractory Celiac Disease With Infliximab in a Pediatric Patient
por: Rawal, Nidhi, et al.
Publicado: (2015)

Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease
por: Nakamura, Akihiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_um31tdb059dbr070bpq7gd5423